Skip to main content
Premium Trial:

Request an Annual Quote

Affitech, Norwegian Radium Hospital Awarded $900K Immunoproteomics Grant

NEW YORK, Feb. 17 (GenomeWeb News) - Affitech, an Oslo, Norway-based antibody discovery firm, said today that Norway's FUGE (Functional Genomics) funding program has awarded it a NOK 6.2 million ($900,000) grant to support a collaborative research project with the Norwegian Radium Hospital.

The award will fund research that Affitech and the hospital began several years ago in the area of cancer immunoproteomics. Researchers from the two organizations are working together to develop techniques to identify tumor-specific or tumor-associated antigens and antibodies.

Affitech said it plans to use human antibodies against tumor-associated antigens to directly attack tumors, while the research team at the Norwegian Radium Hospital will use tumor antigens to stimulate the T-cell dependent arm of the immune system with the goal of creating a cancer vaccine.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.